Answers are grounded in this paper and cite their sources.
We identified an understudied category of patients with LN who accrue progressive renal damage despite apparent response to standard of care therapy. Better definitions and biomarkers of response are needed to improve renal outcomes and trial design.
No takes yet. Share an insight, caveat, or question.
Weeding et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: